Despite increasing knowledge of the roles of BRAF and MSI in CRC, challenges remain in interpreting results and integrating this information into optimal clinical practice, particularly regarding metastatic patterns and therapeutic responsiveness [15]. This evidence concerns the gene BRAF and colorectal carcinoma.